KKR committed $5.89 billion to acquire Integer Holdings, the medical-device manufacturer, in a transaction announced during August when global private equity dealmaking otherwise collapsed. The Integer acquisition becomes the largest healthcare PE transaction of the month and positions KKR's healthcare vertical as the structural winner in a capital environment that punished most sectors. The deal closes in August 2026.

Global private equity activity fell sharply across August, with healthcare the sole sector registering meaningful inflows. KKR's Integer transaction represented the bulk of healthcare's monthly volume, demonstrating that platform-scale assets still command full-cycle pricing when tied to durable end markets. Integer manufactures cardiac rhythm management devices, neuromodulation systems, and surgical tools—categories with installed-base economics that private equity underwrites even when exit timelines stretch. The $5.89 billion figure includes debt assumption and reflects a valuation multiple in line with KKR's prior medical-technology acquisitions, though exact EBITDA multiples were not disclosed.

The significance extends beyond the transaction itself. Healthcare now accounts for the plurality of private equity capital deployment in 2025, reversing the dominance software and industrials held through 2022 and 2023. KKR has methodically assembled a healthcare portfolio exceeding $40 billion in aggregate enterprise value, spanning devices, services, and specialty pharma. Integer fits the archetype: stable margins, regulatory moats, and revenue indexed to aging demographics rather than discretionary budgets. When credit markets tighten and exit windows narrow, healthcare assets generate the cash flow that keeps leverage manageable and IRRs above cost of capital. August's broader PE downturn—driven by financing costs and valuation disagreement—makes KKR's willingness to close at this scale a signal that the firm sees healthcare as counter-cyclical, not merely defensive.

Allocators should monitor three follow-on developments. First, whether KKR syndicates portions of the Integer equity to co-investors or retains full ownership, which will clarify conviction versus balance-sheet management. Second, Integer's integration into KKR's existing Envision Healthcare and MultiPlan portfolios, expected to begin in Q4 2025, will reveal cross-platform synergies or standalone treatment. Third, competitor responses—particularly from Apollo, Blackstone, and EQT—who have flagged healthcare as overweight targets but have not yet deployed at KKR's pace this year. If those firms follow with similar-scale healthcare acquisitions by year-end, the sector repricing becomes consensus rather than opportunistic.

Integer closes in thirty-six months, giving KKR a long runway to extract operational alpha before the next refinancing cycle begins.